.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the general public market.The Eli Lilly-partnered biotech wish to note on the Nasdaq under the symbolic representation “BIOA,” according to documentations submitted along with the Securities and Exchange Percentage. The provider has certainly not openly discussed an assumed financial volume for the offering.The clinical-stage provider proclaims lead candidate azelaprag, an orally provided little particle slated to enter into phase 2 screening in combo with semaglutide– marketed through Novo Nordisk under brand name Wegovy for effective weight loss– in the initial fifty percent of next year. Semaglutide is actually likewise sold as Ozempic and Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually made to incorporate well with GLP-1 medications, enhancing effective weight loss while protecting muscular tissue mass. The investigational medication was actually located to become well-tolerated among 265 people all over eight period 1 tests, according to BioAge.Earlier, BioAge got the support of Lilly to manage a trial blending azelaprag along with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and also Zepbound for effective weight loss. The companions are actually currently carrying out a period 2 test of azelaprag and tirzepatide, with topline results anticipated in the third one-fourth of 2025.The biotech is likewise organizing a blood insulin sensitivity proof-of-concept test assessing azelaprag as a monotherapy in the very first fifty percent of following year to assist potential indication development.
In addition, the company organizes to talk to the FDA for permission in the second fifty percent of 2025 to release individual testing for an NLRP3 prevention targeting metabolic conditions and neuroinflammation.BioAge’s expected move to everyone market complies with a light uptick in organized biotech IPOs coming from Bicara Therapeutics and Zenas Biopharma. Zooming out, the latest IPO garden is actually a “blended photo,” with high-quality companies still debuting on the general public markets, merely in lessened varieties, according to PitchBook.